Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 May;57(5):523-8.
doi: 10.1136/jcp.2003.008599.

The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer

L Nakopoulou  1 , A C Lazaris, E G Panayotopoulou, I Giannopoulou, N Givalos, S Markaki, A Keramopoulos
Affiliations

The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer

L Nakopoulou et al. J Clin Pathol. 2004 May.

Abstract

Aims: Oestrogen receptor beta (ERbeta) is present in breast tumours, although its prognostic and pathophysiological roles remain to be established.

Methods: Standard immunohistochemistry with a specific monoclonal antibody was performed on paraffin wax embedded sections; 10% of strongly immunostained carcinoma cells was used as the cutoff point to classify tumours as ERbeta positive. Statistical correlations were sought with clinicopathological variables (including hormone receptor status) and disease free (DFS) and overall survival (OS) in a well documented series of 181 invasive breast carcinomas. Cell proliferation was assessed immunohistochemically by topoisomerase IIa (TopoIIa) index; p53 protein accumulation and c-erbB-2 oncoprotein expression were also taken into account.

Results: ERbeta immunoreactivity was detected in most specimens (71.2%); it was positively linked to ERalpha immunoreactivity and increased TopoIIalpha index, and inversely to c-erbB-2 overexpression. There were no correlations with p53 immunostaining or other clinicopathological parameters. A significant favourable impact of ERbeta immunopositivity emerged with regard to DFS and OS in both univariate and multivariate analysis; ERbeta immunopositivity retained its favourable significance with regard to DFS in the subgroups of stage I and II patients when they were examined separately. Progesterone receptor expression also had an independent favourable influence on survival, albeit with less significance. In contrast, survival was not significantly influenced by ERalpha status.

Conclusions: Because of the positive association between ERbeta immunoreactivity and TopoIIalpha expression, the presence of ERbeta in breast cancer cells could be considered an indication of increased proliferation. Nevertheless, ERbeta immunoreactivity emerges as a valuable, independent indicator of favourable prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Intense oestrogen receptor β immunopositivity in the nuclei of a lobular invasive carcinoma (avidin–biotin complex immunohistochemical stain; original magnification, ×250).
Figure 2
Figure 2
Oestrogen receptor β immunodetection in both malignant cells and normal ductules (lower left) (avidin–biotin complex immunohistochemical stain; original magnification, ×300).
Figure 3
Figure 3
Statistical associations of (A) oestrogen receptor β (ERβ) immunopositivity and ERα expression in cancer cells (ERα negative, black bars; ERα positive, shaded bars); (B) ERβ immunopositivity and topoisomerase IIa index in cancer cells; (C) ERβ immunopositivity and tissue inhibitor of metalloproteinases 1 (TIMP-1) expression in cancer cells (< 30% cells positive, black bars; > 30% cells positive, shaded bars); and (D) c-erbB-2 expression in cancer cells (c-erbB-2 negative, black bars; c-erbB-2 positive, shaded bars).
Figure 4
Figure 4
The prognostic impact of oestrogen receptor (ER) immunopositivity on disease free and overall survival (all patients; log rank tests).
See this image and copyright information in PMC

References

    1. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists’ Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966–78. - PubMed
    1. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474–81. - PubMed
    1. Jensen EV, Chen G, Palmieri C, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 2001;98:15197–202. - PMC - PubMed
    1. Saji S, Jensen EV, Nilsson S, et al. Estrogen receptors α and β in the rodent mammary gland. Proc Natl Acad Sci U S A 2000;97:337–42. - PMC - PubMed
    1. Speirs V, Skliris GP, Burdall SE, et al. Distinct expression patterns of ERα and ERβ in normal human mammary gland. J Clin Pathol 2002;55:371–4. - PMC - PubMed

Publication types